汉森制药
(002412)
| 流通市值：25.74亿 | | | 总市值：26.32亿 |
| 流通股本：4.92亿 | | | 总股本：5.03亿 |
| 报告期 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 74,792,141.37 | 51,127,203.84 | 65,600,648.7 | 109,095,075.24 |
| 应收票据及应收账款 | 350,546,382.38 | 303,024,192.76 | 281,247,117.68 | 287,200,143.64 |
| 其中：应收票据 | 37,403,627.25 | 43,843,734.47 | 45,717,236.67 | 41,851,244.32 |
| 应收账款 | 313,142,755.13 | 259,180,458.29 | 235,529,881.01 | 245,348,899.32 |
| 应收款项融资 | 41,668,052.47 | 49,498,386.66 | 44,021,602.22 | 44,912,228.86 |
| 预付款项 | 3,496,673.27 | 2,938,999.11 | 4,699,495.1 | 2,583,080.9 |
| 其他应收款合计 | 6,439,843.92 | 8,339,778.57 | 12,945,537.54 | 16,316,446.36 |
| 存货 | 220,524,990.88 | 231,123,272.84 | 241,209,397.82 | 237,447,264.62 |
| 其他流动资产 | 51,891,556.29 | 46,148,550.27 | 20,460,021.54 | 19,387,320.19 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 948,384,774.08 | 896,074,387.79 | 830,305,842.99 | 816,525,600.44 |
| 非流动资产: | | | | |
| 长期股权投资 | 851,940,451.84 | 841,806,928.81 | 817,978,477.94 | 831,263,844.38 |
| 投资性房地产 | 3,553,554.43 | 3,617,727.25 | 3,681,900.07 | 3,746,072.89 |
| 固定资产 | 488,679,469.02 | 497,867,096.66 | 400,948,486.12 | 407,662,640.12 |
| 在建工程 | 11,442,609.36 | 9,082,755.19 | 7,517,229.49 | 6,518,080.48 |
| 生产性生物资产 | 8,695,920.71 | 8,664,764.06 | 8,533,754.24 | 8,279,858.1 |
| 无形资产 | 29,215,160.26 | 29,541,613.18 | 30,666,932.5 | 31,717,968.97 |
| 商誉 | 14,789,430.33 | 14,789,430.33 | 14,789,430.33 | 14,789,430.33 |
| 长期待摊费用 | 14,947,232.57 | 15,126,903.59 | 15,306,574.61 | 15,486,245.63 |
| 递延所得税资产 | 2,397,913.18 | 2,495,142.33 | 1,862,904.67 | 1,917,245.9 |
| 其他非流动资产 | 16,099,277.14 | 17,421,874.74 | 138,148,158.94 | 140,771,265.17 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 1,441,761,018.84 | 1,440,414,236.14 | 1,439,433,848.91 | 1,462,152,651.97 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 2,390,145,792.92 | 2,336,488,623.93 | 2,269,739,691.9 | 2,278,678,252.41 |
| 流动负债: | | | | |
| 短期借款 | 95,120,023.83 | 95,120,023.87 | 90,105,891.98 | 130,131,280.94 |
| 应付票据及应付账款 | 29,216,994.62 | 41,105,375.58 | 29,102,821.8 | 29,889,809.83 |
| 应付账款 | 29,216,994.62 | 41,105,375.58 | 29,102,821.8 | 29,889,809.83 |
| 合同负债 | 1,072,569.05 | 6,476,951.86 | 1,047,109.15 | 1,406,758.44 |
| 应付职工薪酬 | 17,976,613.96 | 45,418,109.84 | 23,954,361.36 | 23,768,601.23 |
| 应交税费 | 11,742,079.05 | 13,927,272.52 | 3,517,858.91 | 4,892,703.3 |
| 其他应付款合计 | 182,938,103.74 | 138,085,240.38 | 226,350,942.95 | 203,271,285.88 |
| 其他流动负债 | 4,530,149.44 | 15,291,632.85 | 13,906,219.84 | 21,830,886.01 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 342,596,533.69 | 355,424,606.9 | 387,985,205.99 | 415,191,325.63 |
| 非流动负债: | | | | |
| 递延收益 | 19,070,520.6 | 16,810,272.08 | 16,410,019.37 | 16,950,683.33 |
| 递延所得税负债 | 1,051,265.71 | 1,224,806.28 | 1,153,541.27 | 1,229,113.05 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 20,121,786.31 | 18,035,078.36 | 17,563,560.64 | 18,179,796.38 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 362,718,320 | 373,459,685.26 | 405,548,766.63 | 433,371,122.01 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 503,200,000 | 503,200,000 | 503,200,000 | 503,200,000 |
| 资本公积 | 234,116,276.27 | 234,116,276.27 | 234,116,276.27 | 234,116,276.27 |
| 其他综合收益 | 16,476,595.9 | 10,342,735.82 | 6,777,288.75 | 6,968,635.59 |
| 盈余公积 | 175,822,549.32 | 175,822,549.32 | 157,692,390.54 | 157,692,390.54 |
| 未分配利润 | 1,097,812,051.43 | 1,039,547,377.26 | 962,404,969.71 | 943,329,828 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 2,027,427,472.92 | 1,963,028,938.67 | 1,864,190,925.27 | 1,845,307,130.4 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 2,027,427,472.92 | 1,963,028,938.67 | 1,864,190,925.27 | 1,845,307,130.4 |
| 负债和股东权益合计 | 2,390,145,792.92 | 2,336,488,623.93 | 2,269,739,691.9 | 2,278,678,252.41 |
| 公告日期 | 2024-04-27 | 2024-04-27 | 2023-10-28 | 2023-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |